Pastor Peptide
← Encyclopedia GLP1s

Tirzeptide Deep Dive

How It Works

Tirzepatide (Mounjaro / Zepbound) is a dual incretin receptor agonist that activates both the GLP-1 and GIP receptors. By targeting these two key metabolic pathways together, it regulates appetite, improves insulin sensitivity, controls blood glucose, and promotes fat loss.

  • GLP-1 → slows gastric emptying, reduces appetite, enhances insulin secretion, and improves blood sugar control.
  • GIP → boosts insulin response in a glucose-dependent way, improves nutrient partitioning, enhances fat metabolism, and may provide additional cardiovascular protection.

This dual action makes Tirzepatide more powerful than GLP-1–only therapies like semaglutide. Unlike Retatrutide, however, Tirzepatide does not activate the glucagon receptor, so it doesn’t directly increase energy expenditure or fat oxidation.

What To Expect

Benefits

  • Weight loss: In large Phase 3 SURMOUNT trials, patients lost up to ~20% of body weight at 72 weeks (15mg dose). Even lower doses (5–10mg) produced substantial loss (~15–18%).
  • Superior efficacy: In head-to-head studies, Tirzepatide outperformed semaglutide in both weight reduction and HbA1c improvement.
  • Glucose control: HbA1c reduced by up to 2.3% in T2D patients; many prediabetics reverted to normal glucose tolerance.
  • Liver health: Trials show significant reductions in liver fat (NAFLD/MASLD), tied to both weight loss and improved insulin sensitivity.

Cardiometabolic benefits: Lowers blood pressure, improves lipid profile (↓ LDL, triglycerides; ↑ HDL), with ongoing CV outcome studies showing promising early signals.

Common Side Effects

  • Gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort (dose-dependent, often improving with time).
  • Heart rate: small mean increase (similar to GLP-1s, usually not clinically significant).Risks & Cautions

Risks & Cautions

  • Gallbladder issues: class-related risk during rapid weight loss.
  • Pancreatitis / thyroid C-cell risk: similar caution as with other GLP-1 therapies.
  • Cardiac monitoring: advisable for those with underlying heart disease until long-term CV data are complete.

Dosing & Protocols

Tirzepatide is FDA-approved, so dosing is standardized. The key is slow titration to minimize GI side effects.

Standard FDA Schedule

  • Weeks 1–4: 2.5mg weekly (for tolerance, not weight loss)
  • Weeks 5–8: 5mg weekly
  • Weeks 9–12: 7.5mg weekly
  • Weeks 13–16: 10mg weekly
  • Weeks 17–20: 12.5mg weekly
  • Weeks 21+: 15mg weekly (max dose)

Minimal-Increase Schedule (for sensitive patients)

  • Weeks 1–8: 2.5mg weekly
  • Weeks 9–16: 5mg weekly
  • Weeks 17+: only increase if weight loss plateaus for 4+ weeks despite consistent lifestyle factors

Important Considerations

  • Lowest effective dose: Many patients achieve excellent results at 5–10mg; 15mg provides modest additional benefit but more side effects.
  • Injection timing: Once weekly, any time of day, with or without food. Some split doses into twice-weekly injections for smoother tolerance.
  • Monitoring: HbA1c, liver enzymes, lipid panel, and optional DEXA scans for fat vs lean mass changes.